Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease

By Jonathan / March 15, 2021

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis). Sio https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-first-patient-dosed-clinical-trial?fbclid=IwAR2DaXAujFySSmtAoEIfDF1XhG3Gi56D6CgDkbMD2yWAFQ65kP28GV3G4B0